Search results for "Oncogene protein"

showing 10 items of 812 documents

Poorly differentiated synovial sarcoma: A case report

2001

Poorly differentiated synovial sarcoma is a rare soft tissue tumor. We studied a case arising in the pleural cavity of a young subject, characterised by the presence of spindle cell, small cell, and large epithelioid cell areas. We performed stains for mucosubstances and analysed the expression of cytokeratins 5/6, 7, 8, 18, 19, CEA, CD34, Ber-Ep4 and calretinin to characterize the phenotype of this neoplasm. We furthermore assessed immunohistochemically the presence of p53, Bcl-2, Bax and caspase 3, four apoptotic markers, to evaluate a relationship between apoptotic activity and the behaviour of this tumor. Our findings showed a strong presence of calretinin, p53 and Bcl-2 in all three ar…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPleural Neoplasms2734CD34Caspase 3Pathology and Forensic MedicineSynovial sarcomaImmunoenzyme TechniquesSarcoma SynovialS100 Calcium Binding Protein GBcl-2-associated X proteinCalretininProto-Oncogene ProteinsBiomarkers TumormedicineHumansCaspasebcl-2-Associated X ProteinbiologyCaspase 3ApoptosiSoft tissue tumorGeneral MedicinePoorly differentiated synovial sarcomamedicine.diseaseSynovial sarcomaNeoplasm ProteinsApoptosis; Calretinin; Poorly differentiated synovial sarcoma; Soft tissue tumors; Synovial sarcoma; Cancer Research; Oncology; 2734Proto-Oncogene Proteins c-bcl-2OncologyCalbindin 2Caspasesbiology.proteinSarcomaTumor Suppressor Protein p53CalretininEpithelioid cell
researchProduct

BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia

2009

BCL6 somatic mutations affect normal and tumoral post germinal center B-lymphocytes. Our objective was to analyse expression, mutations and polymorphisms in the BCL6 gene and to correlate those variables with the clinical outcome in early-stage chronic lymphocytic leukemia (CLL). CLL samples were used for characterisation of the mutational status of BCL6/ immunoglobulin variable heavy chain (IGHV) genes, and expression of BCL6 was determined by real time PCR and immunoblot. Out of 68 cases, 29% show somatic mutations on BCL6 which occur exclusively in IGHV mutated cases. They are single nucleotide substitutions located mainly in two short mutational hot spots. CLL cells express different le…

AdultMaleCancer ResearchSomatic cellChronic lymphocytic leukemiaBiologyPredictive Value of Testsimmune system diseaseshemic and lymphatic diseasesmedicineHumansPoint MutationGeneAgedAged 80 and overPolymorphism GeneticGenes ImmunoglobulinGerminal centerHematologyMiddle AgedPrognosismedicine.diseaseBCL6Leukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsTreatment OutcomeReal-time polymerase chain reactionOncologyMutationImmunologyProto-Oncogene Proteins c-bcl-6biology.proteinFemaleAntibodyImmunoglobulin Heavy ChainsIGHV@Leukemia & Lymphoma
researchProduct

Bcl-2 as prognostic factor in head and neck squamous cell carcinoma

2005

A series of 66 cases of oral squamous cell carcinoma (OSCC) was retrospectively analyzed by immunohisto-chemistry for bcl-2 expression to verify its predictive value for clinical outcome in patients with OSCC. After grouping for bcl-2 expression, OSCCs were statistically analyzed for the variables age, gender, histological grading (G), TNM, staging, recurrence, and overall survival rate. Univariate and multivariate (Cox regression) analyses were performed. Thirty-six OSCC (54.5%) showed expression for bcl-2, whereas 30 (44.5%) were negative. No statistical association was found between bcl-2 expression and any variables considered at baseline. Overall disease-specific survival rate at 72 mo…

AdultMaleEXPRESSIONOncologyCancer Researchmedicine.medical_specialtyPathologyAdolescentSPONTANEOUS APOPTOSISPROTEINBCL-2Internal medicinemedicineCarcinomaHumansPROGNOSTIC SIGNIFICANCEGrading (tumors)Survival rateIMMUNOHISTOCHEMICAL ANALYSISORAL-CAVITYIN-VIVOAgedRetrospective StudiesAged 80 and overProportional hazards modelbusiness.industryCancerRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseImmunohistochemistryCANCERHead and neck squamous-cell carcinomaSurvival RateFAMILY-MEMBERSstomatognathic diseasesProto-Oncogene Proteins c-bcl-2OncologySQUAMOUS CELL CARCINOMAHead and Neck NeoplasmsBAXCarcinoma Squamous CellRegression AnalysisImmunohistochemistryFemalebusinessONCOPROTEIN
researchProduct

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

1998

Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumours. The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance. HPRC is histologically and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8). Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome. Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of b…

AdultMaleGenetic LinkageUrologyMolecular Sequence DataHereditary Papillary Renal Cell CarcinomaChromosomal translocationBiologyurologic and male genital diseasesY chromosomemedicine.disease_causeProto-Oncogene MasGermlineGermline mutationGeneticsmedicineMissense mutationHumansAmino Acid SequenceCarcinoma Renal CellGerm-Line MutationAgedKidneyMutationBinding SitesSequence Homology Amino Acidbusiness.industryReceptor Protein-Tyrosine KinasesMiddle AgedProtein-Tyrosine KinasesProto-Oncogene Proteins c-metmedicine.diseasePenetranceCarcinoma PapillaryKidney NeoplasmsPedigreemedicine.anatomical_structureProto-Oncogene Proteins c-metMutationCancer researchHereditary leiomyomatosis and renal cell carcinomaFemaleTrisomybusinessKidney cancerChromosomes Human Pair 7Nature genetics
researchProduct

Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas

2010

Telomere length alterations are known to cause genomic instability and influence clinical course in several tumor types, but have been little investigated in neuroblastoma (NB), one of the most common childhood tumors. In the present study, telomere-dependent chromosomal instability and telomere length were determined in six NB cell lines and fifty tumor biopsies. The alternative lengthening of telomeres (ALT) pathway was assayed by scoring ALT-associated promyelocytic leukemia (PML) bodies (APBs). We found a reduced probability of overall survival for tumors with increased telomere length compared to cases with reduced or unchanged telomere length. In non-MYCN amplified tumors, a reduced o…

AdultMaleGenome instabilityCancer ResearchBiologyNeuroblastomaYoung AdultCell Line TumorChromosomal InstabilityChromosome instabilityNeuroblastomaGeneticsmedicineHumansChildTelomeraseIn Situ Hybridization FluorescenceAnaphaseOncogene ProteinsN-Myc Proto-Oncogene ProteinOncogeneGene AmplificationInfant NewbornInfantNuclear ProteinsTelomeremedicine.diseaseMolecular biologyTelomereLeukemiaCell cultureChild PreschoolFemaleAnaphase
researchProduct

Variation in genomic landscape of clear cell renal cell carcinoma across Europe

2014

The incidence of renal cell carcinoma (RCC) is increasing worldwide, and its prevalence is particularly high in some parts of Central Europe. Here we undertake whole-genome and transcriptome sequencing of clear cell RCC (ccRCC), the most common form of the disease, in patients from four different European countries with contrasting disease incidence to explore the underlying genomic architecture of RCC. Our findings support previous reports on frequent aberrations in the epigenetic machinery and PI3K/mTOR signalling, and uncover novel pathways and genes affected by recurrent mutations and abnormal transcriptome patterns including focal adhesion, components of extracellular matrix (ECM) and …

AdultMaleOncogene Proteins FusionRNA SplicingGeneral Physics and AstronomyBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyCohort StudiesTranscriptomePhosphatidylinositol 3-KinasesMutation RatemedicineHumansEpigeneticsCarcinoma Renal CellAgedAged 80 and overGeneticsFocal AdhesionsMutationMultidisciplinaryGenome HumanGene Expression ProfilingGenetic VariationGenomicsSequence Analysis DNAGeneral ChemistryMiddle Agedmedicine.diseaseHuman genetics3. Good healthEuropeGene Expression Regulation NeoplasticGene expression profilingClear cell renal cell carcinomaMutationFemaleCarcinogenesisClear cellSignal TransductionNature Communications
researchProduct

Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia

2004

In B-cell chronic lymphocytic leukemia (B-CLL), somatic mutation of IgVH genes defines a subgroup with favorable prognosis, whereas the absence of IgVH mutations is correlated with a worse outcome. Mutations of the BCL-6 gene are also observed in a subset of B-CLL, but the clinical significance of this molecular alteration remains uncertain. We examined the distribution of IgVH and BCL-6 gene mutations in 95 well-characterized patients with Binet stage A B-CLL, and correlated them with clinical, laboratory, cytogenetic findings and disease progression. Mutations of the BCL-6 gene were observed only in cases harboring mutated IgVH. Unexpectedly, coexistence of IgVH and BCL-6 mutations was co…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyChronic lymphocytic leukemiaImmunoglobulin Variable RegionLocus (genetics)BiologyGene mutationDisease-Free SurvivalGermline mutationProto-Oncogene ProteinsInternal medicinemedicineHumansB-cell chronic lymphocytic leukemiaClinical significanceProspective StudiesGeneAgedAged 80 and overHematologyChromosomes Human Pair 11HematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsOncologyMutationImmunologyProto-Oncogene Proteins c-bcl-6FemaleChromosome DeletionChromosomes Human Pair 17Follow-Up StudiesTranscription FactorsLeukemia
researchProduct

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

2008

Abstract Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuximab- and panitumumab-based treatments in metastatic colorectal cancer (CRC) patients. Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases. Patients and Methods. We analyzed KRAS codon 12 and 13 mutations from formalin-fixed sections of 107 CRC primaries and related metastases. Eight pairs were excluded from the analysis because of the low amount of tumor tissue in the available samples. The main characteristics were: 50 men, 49 women; me…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyColorectal cancerConcordancemedicine.disease_causeProto-Oncogene Proteins p21(ras)Proto-Oncogene ProteinsInternal medicinemedicineHumansPanitumumabNeoplasm MetastasisneoplasmsAgedRetrospective StudiesAged 80 and overCetuximabbusiness.industryRetrospective cohort studyMiddle Agedmedicine.diseasedigestive system diseasesConfidence intervalErbB ReceptorsClinical PracticeGenes rasOncologyMutationras ProteinsFemaleKRASKRAScolorectal tumorsColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia

2004

Abstract This phase 2 pilot study was conducted to determine the efficacy and safety of imatinib mesylate in patients with c-kit–positive acute myeloid leukemia (AML) refractory to or not eligible for chemotherapy. Twenty-one patients were enrolled and received imatinib 600 mg orally once daily. Five responses were seen primarily in patients, starting with relatively low blast counts in bone marrow (BM) and peripheral blood (PB): 2 patients who were considered refractory on chemotherapy on the basis of persistence of blasts in PB and BM met the criteria for complete hematologic remission, 1 patient had no evidence of leukemia, and 2 patients achieved a minor response. Treatment with imatini…

AdultMaleOncologymedicine.medical_specialtyAdolescentmedicine.medical_treatmentDNA Mutational AnalysisImmunologyAntineoplastic AgentsCell CountPilot ProjectsBiochemistryPiperazineshemic and lymphatic diseasesInternal medicineHumansMedicinePhosphorylationneoplasmsAgedSalvage TherapyChemotherapybusiness.industryRemission InductionMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseImmunohistochemistryClinical trialProto-Oncogene Proteins c-kitLeukemiaPyrimidinesTreatment OutcomeImatinib mesylatemedicine.anatomical_structureLeukemia MyeloidAcute DiseaseBenzamidesImmunologyImatinib MesylateImmunohistochemistryFemaleBone marrowBlast Crisisbusinessmedicine.drugBlood
researchProduct

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Grou…

2010

Background: To assess whether deletions involving codons 557 and/or 558 (critical deletions) of exon 11 of KIT are relevant in the prognosis of relapse-free survival (RFS) in gastrointestinal stromal tumor (GIST) patients with a long follow-up. Patients and methods: A univariate and multivariate analysis for RFS were carried out on 162 localized GIST patients over the entire follow-up period and over the intervals 0-4 years and >4 years. Factors assessed among others were Fletcher/National Institutes of Health and Miettinen-Lasota/Armed Forces Institute of Pathology (M-L/AFIP) risk categories, critical deletions and non-deletion-type mutation (NDTM) within exon 11 of KIT. Results: Multivari…

AdultMaleOncologymedicine.medical_specialtyTime FactorsMultivariate analysisAdolescentGastrointestinal Stromal TumorsYoung AdultInternal medicinemedicineHumansStromal tumorChildCodonSurvival rateSequence DeletionGiSTbusiness.industryInfant NewbornInfantCancerHematologyMiddle Agedmedicine.diseaseConfidence intervalSurgerySurvival RateProto-Oncogene Proteins c-kitTreatment OutcomeOncologyChild PreschoolRelative riskFemaleSarcomaNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of Oncology
researchProduct